Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology (CROSBI ID 235348)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Kostović, Krešimir ; Jerković Gulin, Sandra ; Bukvić Mokos, Zrinka ; Čeović, Romana Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology // Current medicinal chemistry, 24 (2017), 11; 1158-1167. doi: 10.2174/1874467210666170113104503

Podaci o odgovornosti

Kostović, Krešimir ; Jerković Gulin, Sandra ; Bukvić Mokos, Zrinka ; Čeović, Romana

engleski

Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology

Tofacitinib (formerly known as CP- 690, 550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology. We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included. Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata. JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.

tofacitinib ; CP690550 ; protein kinase inhibitor ; JAK/STAT pathway ; small molecule ; psoriasis ; alopecia areata ; vitiligo

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

24 (11)

2017.

1158-1167

objavljeno

0929-8673

1875-533X

10.2174/1874467210666170113104503

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost